Oceanpine Capital Leads $80M Series B Round In China-US Biotech Firm Ansun BioPharma

Ansun BioPharma, a China-US based clinical stage biopharmaceutical company, has raised US$80 million in a series B round of financing led by Chinese investment management firm Oceanpine Capital, according to a statement released on Monday. Chinese government-backed Greater Bay Area Homeland Development Fund, Hong Kong-based private equity firm Junson Capital, Korea Investment Partners (KIP) and […]

Oceanpine Capital Leads $80M Series B Round In China-US Biotech Firm Ansun BioPharma comes originally from China Money Network. All Rights Reserved.

Read the original article: China Money Network